Scalper1 News
Biotech BioMarin Pharmaceutical (BMRN) agreed Monday to pay $680 million in cash for Prosensa Holding, developer of a muscular-dystrophy drug with a checkered history. Prosensa soared 63%, while BioMarin slipped a fraction in early trading in the stock market today. The deal also included two milestone payments of $80 million each if Prosensa’s (RNA) lead drug drisapersen is approved for Duchenne’s muscular dystrophy (DMD) in the U.S. no later Scalper1 News
Scalper1 News